[Edaily Reporter Park Jung-Soo ] On the 30th, NH INVESTMENT & SECURITIES assessed that the commercialization of #Inventera Inc.’s gadolinium-free MRI contrast agent is becoming a reality, and that the company is expected to expand into a therapeutic platform in the future. The firm did not provide an investment rating or target price. The previous day’s closing price was 9,530 won.

Han Seung-yeon, an analyst at NH INVESTMENT & SECURITIES, stated, “INV-002, the company’s core pipeline, is in the final stages of Phase 3 trials in Korea; the key milestones are the submission of a marketing authorization application in the second half of 2026 and a domestic launch in 2027.” She added, “In the medium to long term, attention should also be paid to the scalability of Invinity-based therapeutics.”
Inventera Inc. is a company developing contrast agents and therapeutics based on its polysaccharide-based nanostructure platform, “Invinity.” The company explains that it has addressed issues—such as protein corona formation, phagocytosis by immune cells, and particle aggregation—which were previously considered limitations of existing nanomedicines, and that it can expand its application scope beyond contrast agents to include small-molecule therapeutics and antibody-drug conjugates (ADCs).
Its core pipeline candidate, INV-002, is an iron-based MRI contrast agent specifically designed for MRA (magnetic resonance arthrography). While off-label use of diluted gadolinium contrast agents is currently common for MRA, INV-002 is expected to become the first approved product with an MRA indication upon its launch. Interim analysis of the domestic Phase 3 trial confirmed improvements in both primary and secondary endpoints.
An analyst explained, “After securing the Clinical Study Report (CSR) in the third quarter, we plan to apply for marketing authorization in the second half of the year, with domestic sales expected to begin in the second or third quarter of 2027.” The analyst added, “LGCHEM,LTD will be responsible for the active pharmaceutical ingredient (API), while DongKook Life Science Co., Ltd. will handle the production and sales of the finished drug product for commercialization.” He added, “Approximately 45% of the final sales price will be reflected in Inventera Inc.’s revenue, and the company will also receive royalties linked to net sales.”
The company’s follow-on pipeline is also progressing smoothly. The lymphatic contrast agent INV-001 has received approval for a Phase 2a trial in Korea and an Investigational New Drug (IND) application for a Phase 2 trial in the U.S., while the oral pancreaticobiliary contrast agent INV-003 aims to enter clinical trials in both Korea and the U.S. within the year.
One analyst noted, “Technology transfers are expected around 2028, as global clinical data for INV-002 and INV-001 accumulates,” adding, “In the long term, the potential to expand into therapeutic areas such as drug-conjugates and ADCs using the Invinity platform will be a factor driving the company’s value.”